Exhibit 99.1
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that
members of its management team will present and host investor meetings at the following investor conferences in March 2019:
Kevin Trapp, Chief Commercial
Officer, and Susanna Mesa, Chief Business Officer, will present at the Barclays Global Healthcare Conference in Miami, FL, on Wednesday, March 13, 2019, at 10:45am ET.
Kevin Trapp, Chief Commercial Officer, and Susanna Mesa, Chief Business Officer, will host investor meetings at the Morgan Stanley Healthcare Corporate Access
Day in Boston, MA, on Tuesday, March 19, 2019.
A live webcast of the presentation at the Barclays Global Healthcare Conference will be available on
the Investors & Media section of the Companys website:
https://www.dbv-technologies.com/investor-relations/
. A replay of the presentation will also be available on DBVs website
within three hours after the event.
About DBV Technologies
DBV Technologies is developing Viaskin
®
, a proprietary technology platform with broad potential
applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT
®
, DBVs method of delivering biologically active compounds to the immune system through intact skin.
With this new class of self-administered and
non-invasive
product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments.
DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human
proof-of-concept
clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other
immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the
Companys ADSs (each representing
one-half
of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
DBV Investor Relations Contact
Sara Blum Sherman